Beryl Drugs Balance Sheet Health
Financial Health criteria checks 4/6
Beryl Drugs has a total shareholder equity of ₹90.2M and total debt of ₹49.6M, which brings its debt-to-equity ratio to 55%. Its total assets and total liabilities are ₹192.8M and ₹102.6M respectively. Beryl Drugs's EBIT is ₹18.7M making its interest coverage ratio 4.9. It has cash and short-term investments of ₹4.4M.
Key information
55.0%
Debt to equity ratio
₹49.62m
Debt
Interest coverage ratio | 4.9x |
Cash | ₹4.42m |
Equity | ₹90.16m |
Total liabilities | ₹102.63m |
Total assets | ₹192.79m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 524606's short term assets (₹117.3M) exceed its short term liabilities (₹73.5M).
Long Term Liabilities: 524606's short term assets (₹117.3M) exceed its long term liabilities (₹29.1M).
Debt to Equity History and Analysis
Debt Level: 524606's net debt to equity ratio (50.1%) is considered high.
Reducing Debt: 524606's debt to equity ratio has increased from 31.8% to 55% over the past 5 years.
Debt Coverage: 524606's debt is well covered by operating cash flow (46.2%).
Interest Coverage: 524606's interest payments on its debt are well covered by EBIT (4.9x coverage).